Modeling the Transitional Phase of Epithelial Cells Reveals Prognostic and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

TL;DR

This study identifies key transitional epithelial cells in pancreatic cancer, offering new ways to predict outcomes and develop targeted treatments.

Contribution

The study introduces a gene-based risk score model for pancreatic cancer prognosis and treatment prediction.

Findings

A gene-based risk score model accurately predicts patient prognosis and chemotherapy sensitivity.

Collagen signaling mediates interactions between fibroblasts and transitional epithelial cells, contributing to PDAC fibrosis.

Altered NK cell infiltration in high-risk patients suggests immune tolerance mechanisms in PDAC.

Abstract

Pancreatic cancer is a highly aggressive disease that is often diagnosed too late for effective treatment. This study focuses on a group of epithelial cells that appear to undergo a key transition during early tumor development. By closely examining these cells, we identified specific gene patterns that can be used to assess disease severity and predict patient outcomes. The findings also highlight how certain fibroblasts in the tumor environment may contribute to cancer progression by influencing these transitional cells. Moreover, differences in immune cell presence, especially natural killer cells, were observed in patients with higher risk levels. Together, these insights may support earlier diagnosis, more accurate risk assessment, and the development of tailored treatment approaches for pancreatic cancer.

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis, and its progression is driven by epithelial plasticity and tumor microenvironment remodeling. Finding biomarkers that are responsible for the turning point from the early stage to the aggressive phase would facilitate clinical management. Method: In this study, we employed single-cell RNA sequencing to characterize a distinct subpopulation of highly proliferative epithelial cells undergoing a transitional phase during PDAC progression. By linking to cell cycle dysregulation, epithelial differentiation, and clinical staging, we constructed a gene-based risk score model using Lasso Cox regression. The expression of selected genes within the model was further validated using qPCR. Results: The model demonstrated robust predictive power for patient prognosis, TNM staging, and chemotherapy sensitivity. Further analysis of the tumor microenvironment revealed intensified crosstalk between a specific fibroblast subpopulation and transitional epithelial cells, mediated largely by collagen signaling. This stromal–epithelial interaction was found to contribute to the fibrotic barrier characteristic of PDAC. Additionally, immune profiling uncovered altered infiltration patterns, particularly involving natural killer (NK) cells in high-risk patients, suggesting mechanisms of immune tolerance and inhibition. Conclusions: These findings offer potential avenues for early detection, risk stratification, and targeted therapeutic strategies in PDAC.

Figures